Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Lymphoid 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 2Carcinoma, Hepatocellular 2Stomach Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Diseases 1Neuroblastoma 1Neoplasm Metastasis 1Medulloblastoma 1Liver Neoplasms 1Hepatoblastoma 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1Fibrosis 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma 1Breast Neoplasms 1Basal Cell Nevus Syndrome 1Astrocytoma 1

Interventions

Bevacizumab 6Nivolumab 5pembrolizumab 4Gemcitabine 4Cisplatin 3regorafenib 2fludarabine 2Sorafenib 2Paclitaxel 2Oxaliplatin 2Leucovorin 2Irinotecan 2Fluorouracil 2Drug Therapy 2Cyclophosphamide 2Azacitidine 2vocimagene amiretrorepvec 1ulixertinib 1temsirolimus 1spartalizumab 1sonidegib 1selinexor 1sargramostim 1sacituzumab govitecan 1ruxolitinib 1rucaparib 1pazopanib 1olutasidenib 1olaparib 1motexafin gadolinium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × sonidegib × Gastrointestinal × Clear all
NCT01576666 2020-12-19

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
120 enrolled
BreastCNSGastrointestinal

Breast Neoplasms, Glioblastoma, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡